Natera Inc. presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting significant growth in its core business areas. The company reported record test volumes in the fourth quarter, driven by continued momentum across its product portfolio, including notable sequential growth for its Signatera™ test and strong interest in the Fetal Focus™ offering. Natera also announced the launch of its 21-gene Fetal Focus single-gene noninvasive prenatal test (NIPT), featuring ultrasensitive technology and flexible ordering options. Financially, the company reported approximately 39% year-over-year revenue growth for the fourth quarter of 2025 and generated more than $100 million in free cash flow during the year. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.